ErbB receptor expression and growth response to heregulin β1 in five ovarian carcinoma lines

International Journal of Oncology

Volumn 14, Issue 6, 1999, Pages 1169-1176

  Pegues, Joyce C ^a   Kannan, Bhanu ^a   Stromberg, Kurt ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Carcinoma; ErbB receptors; Heregulin; Ovarian

Indexed keywords

CARRIER PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; GROWTH PROMOTOR; HEREGULIN BETA1; NEU DIFFERENTIATION FACTOR;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL DIVISION; FEMALE; GLYCOPROTEINS; GROWTH SUBSTANCES; HUMANS; NEUREGULIN-1; OVARIAN NEOPLASMS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0033146531     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bacus SS, Zelnick CR, Plowman G and Yarden Y: Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers: implications for tumor biology and clinical behavior. Am J Clin Pathol 102 (Suppl. 1): S13-S24, 1994.
2. Alroy I and Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86, 1997.
3. Burden S and Yarden Y: Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18: 847-855, 1997.
4. Tzahar E, Pinkas-Kramarski R, Moyer J, Klapper L, Alroy I, Levkowitz G, et al: Bivalence of EGF-like ligands drives the erbB signaling network. EMBO J 16: 4938-4950, 1997.
5. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin B, Sela M and Yarden Y: Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467, 1996.
6. Reise DJ II and Stern DF: Specificity within the EGF family/erbB receptor family signaling network. Bioessays 20: 41-48, 1998.
7. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al: A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996.
8. Gamett DC, Pearson G, Cerione RA and Freidberg I: Secondary dimerization between members of the epidermal growth factor receptor family. J Biol Chem 272: 12052-12056, 1997.
9. Earp HS, Dawson TL, Li X and Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115-132, 1995.
10. Graus-Porta D, Beerli R, Daly J and Hynes N: ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997.
11. Disis ML and Cheever MA: Her-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71: 343-371, 1997.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Kieth DE, et al: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 255: 707-712, 1989.
13. Pegram MD, Finn RS, Arzoo K, Beryt M, Peitras RJ and Slamon DJ: The effect of Her2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537-547, 1997.
14. erbB-3 possess impaired kinase activity. Proc Natl Acad Sci USA 91: 8132-8136, 1994.
15. Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D and Yarden Y: Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J 12: 961-971, 1993.
16. Wallasch C, Weiss FLJ, Niederfellner G, Jallal B, Issing W and Ullrich A: Heregulin-dependent regulation of Her2/neu oncogenic signaling by heterodimerization with HER-3. EMBO J 14: 4267-4275, 1995.
17. Lewis G, Lofgren J, McMurtrey AE, Nuijens A, Fendly B and Bauer K: Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of erbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 56: 1457-1465, 1996.
18. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al: Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821, 1995.
19. 185 erbB-2 and erbB-3. Cell Growth Differ 7: 551-561, 1996.
20. Beerli R and Hynes N: Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differences in their biological activities. J Biol Chem 271: 6071-6076, 1996.
21. Daly J, Jannot C, Beerli R, Graus-Porta D, Maurer F and Hynes N: Neu differentiation factor induces erbB2 down-regulation and apoptosis of erbB-overexpressing breast tumor cells. Cancer Res 57: 3804-3811, 1997.
22. Staebler A, Sommers C, Mueller SC, Byers S, Thomson EW and Lupu R: Modulation of breast cancer progression and differentiation by the gp30/heregulin. Breast Cancer Res Treat 31: 175-182, 1994.
23. c-erbB2: increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3: 1629-1634, 1997.
24. Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, et al: Neu differentiation factor (Heregulin) induces expression of intercellular adhesion moledule I: implications in mammary tumors. Cancer Res 53: 5251-5261, 1993.
25. Beerli R, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y and Hynes N: Neu differentiation factor activation of erbB-3 and erbB-4 is cell specific and displays a differential requirement for erbB-2. Mol Cell Biol 15: 6496-6505, 1995.
26. Fitzpatrick VD, Pisacanc PI, Vandlen RL and Sliwkowski M: Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett 431: 102-106, 1998.
27. Chen X, Levkowitz G, Liu N, Wen D and Yarden Y: An immunological approach reveals biological differences between the two NDF/heregulin receptors, erbB-3 and erbB-4. J Biol Chem 270: 9982-9990, 1995.
28. rbB-2. Science 256: 1205-1210, 1992.
29. Reise DJ II, Bermingham Y, van Raaij TM, Buckley S, Plowman GD and Stern DF: Beta-cellulin activates the epidermal growth factor receptor and erbB-4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. Oncogene 12: 345-363, 1996.
30. Komurasaki T, Toyoda H, Uchida D and Morimoto S: Epiregulin binds to epidermal growth factor receptor and erbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, erbB-2, erbB-3 and erbB-4. Oncogene 15: 2841-2848, 1997.
31. Grasso AW, Duanzhi W, Miller CM, Rhim JS, Pretlow TG and Kung H: ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 15: 2705-2716, 1997.
32. Westphal M, Meima L, Szonyi E, Lofgren J, Meissner H, Wolfgang H, et al: Heregulins and the erbB-2/3/4 receptors in gliomas. J Neurooncol 35: 335-346, 1997.
33. Hamburger A and Yoo J: Phosphatidylinositol-3-kinase mediates heregulin-induced growth inhibition in human epithelial cells. Anticancer Res 17: 2197-2200, 1997.
34. Reese DM and Slamon DJ: Her-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1-8, 1997.
35. O'Rourke DM, Zhang X and Greene MI: Principles of receptor based inhibition of erbB family receptor kinases: prospects for new therapies for human cancer. Proc Assoc Am Physicians 109: 209-219, 1998.
36. Her2, promotes ovarian tumor cell activation. J Biol Chem 272: 27913-27918, 1997.
37. Elenius K, Subroto P, Allison G, Sun J and Klagsbrun M: Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16: 1268-1278, 1997.